GNLX Stock Forecast: Genelux Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for Genelux Corp. is $17. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 14 of 100 as at 18 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Genelux Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
GNLX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GNLX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Mar 2026 | Benchmark | Maintains | Speculative Buy | $23 → $20 |
| 21 Oct 2025 | Lake Street | Initiates | Buy | — |
| 21 July 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 8 May 2025 | Benchmark | Maintains | Speculative Buy | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Oct 2024 | Guggenheim | Initiates | Buy | — |
| 27 Aug 2024 | Roth MKM | Initiates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 June 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 31 May 2024 | Benchmark | Maintains | Speculative Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Nov 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 24 Nov 2023 | Benchmark | Maintains | Speculative Buy | — |
| 12 Sept 2023 | Maxim Group | Initiates | Buy | — |
| 9 June 2023 | Benchmark | Maintains | Speculative Buy | — |
| 18 May 2023 | Brookline Capital | Initiates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GNLX.
This page is one stock. Monday covers all of them.
GNLX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
GNLX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Genelux Corp. returned −54.4% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GNLX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 13698.3×
- Price / book
- 11.3×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 7% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- −273.2%
- Return on assets
- −105.9%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Genelux Corp. has a market value of $109.6M and an enterprise value of $99.6M.
Revenue in the twelve months to 30 June 2026: $8K.
Net income over the same four quarters: −$35.6M, a −444950.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$28.7M.
Genelux Corp. employs 25 people — $320.0 of revenue per employee.
Data provided by Twelve Data
GNLX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at GNLX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Genelux Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about GNLX
What is the GNLX stock price forecast for 2026-2027?
The median 12-month analyst price target for Genelux Corp. is $17, with estimates ranging from $12 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GNLX stock a buy right now?
Of the 6 analysts covering Genelux Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genelux Corp. 14 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GNLX?
As at 18 Nov 2026, Genelux Corp. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).
Will GNLX stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $17, and Ticker Nerd's factor model ranks Genelux Corp. 14 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GNLX stock forecast for 2030?
No analyst covering Genelux Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $31 over the next 12 months.
How has GNLX stock performed over the past year?
Genelux Corp. returned -54.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Genelux Corp. do?
Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response.
About Genelux Corp.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response. The company also advances CHOICE, a discovery and development platform, alongside a broader pipeline of engineered virus-based product candidates. Genelux serves the oncology market through drug research, development, and clinical trial services centered on immuno-oncology applications. Headquartered in Westlake Village, California, Genelux Corporation concentrates on current therapeutic programs and specialty biotechnology solutions aimed at addressing unmet needs in cancer treatment.
CEO Mr. Thomas D. Zindrick J.D. · 25 employees · United States · https://www.genelux.com